Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Halozyme Acquires Surf Bio for up to $400M | Contract Pharma

What are you searching for?

Sign in
Breaking News

Halozyme Acquires Surf Bio for up to $400M

Expands drug delivery opportunity with Surf Bio’s hyperconcentration technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Halozyme has acquired Surf Bio for an upfront payment of $300 million, subject to customary purchase price adjustments, and up to $100 million milestone payments based on product development and regulatory approval milestones, for a total consideration of up to $400 million.

Launched in 2021 by the founders of Bigfoot Biomedical and Mode AGC, Surf Bio is a preclinical biopharmaceutical company that develops drug delivery technologies to transform how antibodies and biologics are delivered to patients.

The Surf Bio hyperconcentration technology is being developed to enable high concentrations of up to 500 mg/mL across a wide range of therapeutics, including monoclonal antibodies and small molecules, for delivery in a single auto-injector shot for at-home or in-HCP office use. These high concentration formulations are achievable using Surf Bio’s protective excipient and spray dry approach, enabling accessible and patient-friendly subcutaneous delivery of antibodies and biologics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics